Andrea Gabrio, Necdet B Gunsoy, Gianluca Baio, Alan Martin, Victoria F Paly, Nancy Risebrough, David M G Halpin, Dave Singh, Robert A Wise, MeiLan K Han, Fernando J Martinez, Gerard J Criner, Neil Martin, David A Lipson, Afisi S Ismaila
Objectives: In the IMPACT trial (NCT02164513), triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) showed clinical benefit compared with dual therapy with either FF/VI or UMEC/VI in the treatment of chronic obstructive pulmonary disease (COPD). We used data from IMPACT to determine whether this translated into differences in COPD-related healthcare resource utilization (HRU) costs in a United Kingdom (UK) setting. Methods: In a within-trial analysis, individual patient data from the IMPACT intention-to-treat (ITT) population were analyzed to estimate rates of COPD-related HRU with FF/UMEC/VI, FF/VI, or UMEC/VI...
2022: International Journal of Chronic Obstructive Pulmonary Disease